One of the major culprit gene in RCC is Von-Hippel-Lindau (VHL), whose loss leads to a constitutively active hypoxia inducible factor (Hif) pathway. Target genes of Hif transcription factors include those involved in angiogenesis, vasculogenesis and glycolysis pathways, among others. Drugs have been developed that target the vascular endothelial growth factor (VEGF) and its receptors downstream of Hif or those that target the mTOR pathway which regulates Hif translation. For more information, including adverse effects check PMIDs 20456985, 22099727, 22235142. The drugs are listed by their targets, some have available interactive pathway diagrams.
Targeting VEGF receptors:
axitinib – drug, drug pathway
pazopanib – drug
sorafenib – drug
sunitinib – drug
Targeting VEGF:
bevacizumab – drug
